Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

StatusUnknown
PhasePhase 1
Started

Record status This record was last updated January 14, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Site contacts updated at 1 of 6 sitesv6
  3. Study sites: 3 to 6v5
  4. Enrollment target: 50 to 75v4 Show 6 more changesShow less
    • Primary completion date: Jun 2024 to May 2025
    • Study completion date: Sep 2024 to May 2025
    • Eligibility criteria expanded, about 47 words
    • Study description expanded, about 14 words
    • Study arms: 1 to 3
    • Study title expanded, about 3 words
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2022 to Dec 21, 2022
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Epigenetix, Inc.
1 trial monitored
See all monitored trials
Leukemia
2,957 trials monitored
See 176 trials at risk
Prostate Cancer
2,550 trials monitored
See 165 trials at risk
Myelofibrosis
192 trials monitored
See 11 trials at risk
and 1 more disease
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
Trial Details
NCT Number NCT05488548
Lead Sponsor Epigenetix, Inc.
Conditions
(from sponsor)		 Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
Related terms Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov